Clinical response in metastatic castration-resistant prostate cancer (mCRPC) cases treated with supra-physiological doses of testosterone: Bipolar androgen therapy

Senji Hoshi; Vladimir Bilim; Kiyotsugu Hoshi; Takuya Nakagawa; Sadanobu Sato; Rie Sakagami; Masato Konno; Takashi Kudo; Kenji Numahata; Isoji Sasagawa

doi:10.1002/ccr3.5433

Clinical response in metastatic castration-resistant prostate cancer (mCRPC) cases treated with supra-physiological doses of testosterone: Bipolar androgen therapy

Clin Case Rep. 2022 Feb 10;10(2):e05433. doi: 10.1002/ccr3.5433. eCollection 2022 Feb.

Authors

Affiliations

¹ Department of Urology Yamagata Tokushukai Hospital Yamagata Japan.
² Department of Urology Kameda Daiichi Hospital Niigata Japan.
³ Department of Urology Yamagata Prefectural Central Hospital Yamagata Japan.

Abstract

Androgen deprivation therapy is a standard of care for metastatic prostate cancer. A paradoxical approach utilizing high doses of testosterone in castration-resistant prostate cancer patients demonstrated clinical responses. Here, we report on four heavily pretreated Japanese patients (including one patient on hemodialysis) successfully treated with supra-physiological doses of testosterone.

Keywords: bipolar androgen therapy; metastatic castration‐resistant prostate cancer; prostate cancer; testosterone injection.

Publication types

Case Reports